IOT Innovotech Inc

Innovotech Inc. (TSX VENTURE:IOT), a pioneer in the field of biofilm product
development, has secured funding in excess of $900,000 from Agriculture and
Agri-Food Canada to facilitate the commercialization of Agress(TM), its unique,
environmentally friendly seed treatment and plant spray designed to protect
crops against both bacterial and fungal infections.


"With the potential to increase crop yields and improve product quality while
minimizing the risk of antibacterial resistance, Agress(TM) has the opportunity
to provide a cost-effective solution for the Agricultural Industry where current
technologies either have undesirable effects on the environment or do not work
well," said Ken Boutilier, President and CEO of Innovotech Inc.


The two year, repayable funding, administered in Alberta through the Agriculture
and Food Council, will focus on field trials to expand the potential
applications of Agress(TM) from pulse crops (dry beans, dry peas, lentils,
chickpeas) and soybeans to high value horticultural crops such as tomatoes,
peppers, and potatoes. The funding will also be used to support regulatory
approval submissions for Agress(TM). 


About Innovotech Inc.:

Innovotech Inc. is a pioneer in the field of biofilm product development,
focused on providing innovative and practical solutions to medical, agricultural
and industrial problems caused by microbial biofilms. Biofilms are responsible
for a host of diseases both in agriculture and human health due to their
inherent resistance to existing antibiotics and disinfectants. There are
currently no antibiotics, disinfectants, diagnostics or regulatory standards
designed specifically for biofilm-forming organisms. 


Innovotech currently has two products in advanced stages of development:
Agress(TM) a unique, environmentally friendly seed treatment and plant spray
designed to protect crops against both bacterial and fungal infections, and
bioFILM PA(TM), the first diagnostic kit to assist physicians in the selection
of the most effective combination antibiotic treatment of patients with
biofilm-based chronic lung infections.


This document may contain forward-looking statements that are predictive in
nature and subject to risks and uncertainties that cannot be predicted or
quantified; consequently, actual results may differ materially from past results
and those expressed or implied by any forward-looking statements. Factors that
could cause or contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of predicting
regulatory outcomes; changes in the value of the Canadian dollar; the Company's
reliance on a small number of customers including government organizations;
fluctuations in operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships; uncertainty
related to intellectual property protection and potential costs associated with
its defense; the Company's exposure to lawsuits and other matters beyond the
control of management. Should known or unknown risks or uncertainties
materialize, or should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company undertakes no
obligation to publicly make or update any forward-looking statements, except as
required by applicable law.

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jul 2023 to Jul 2024